Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research

Friday, April 18, 2008 General News J E 4
PALO ALTO, Calif., April 17 Telik, Inc.(Nasdaq: TELK), a biopharmaceutical company focused on discovering anddeveloping drugs to treat serious diseases, today announced that it made fourpreclinical data presentations at the 99th Annual Meeting of the AmericanAssociation for Cancer Research (AACR) in San Diego, Calif. The abstractshighlighted results from Telik's Research and Development programs.

Identification and Characterization of Novel Tyrosine Kinase InhibitorsTargeting Vascular Endothelial Growth Factor Receptor 2 [Abstract # 1439]

Mechanism of Induction of Apoptosis by TLK199 (TELINTRA(R)) in HumanLeukemia Cell Lines [Abstract # 2270]

Identification of a Novel Class of Nonpeptidyl Small-Molecule Inhibitorsof the Human Proteasome [Abstract # 3271]

Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer DrugDiscovery at Telik [Abstract # 4754]

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused ondiscovering, developing and commercializing novel small molecule drugs totreat serious diseases. The company's most advanced investigational drugcandidates in clinical development are TELINTRA, a modified glutathione analogfor the treatment of cytopenias due to myelodysplastic syndrome orchemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment ofadvanced ovarian cancer and non-small cell lung cancer. Telik's productcandidates were discovered using its proprietary drug discovery technology,TRAP, which enables the rapid and efficient discovery of small molecule drugcandidates.

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks orregistered trademarks of Telik, Inc.Inhibition of the vascular endothelial growth factor receptor signaling pathway with antibodies or small molecules has been proven effective as an anti-cancer therapy. Through the use of Telik's Target-Related Affinity Profiling (TRAP(R)) screening technology, novel inhibitors of VEGFR2 kinase were discovered. The inhibitors belong to nine structural classes, among which E2B8 and EAAF are sub-micromolar inhibitors of the kinase.

SOURCE Telik, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
LifeCell Corporation Schedules First Quarter 2008 ...
What You Don't Know Could Hurt You